A Switch Therapy Protocol with Intravenous Azithromycin and Ciprofloxacin Combination for Severe, Relapsing Chronic Bacterial Prostatitis: a Prospective Non-comparative Pilot Study by Adela Kolumbić Lakoš et al.
MEDICUS 2012. Vol. 21, No. 1, 153 - 158
153
Summary Chronic bacterial prostatitis (CBP) is charac-
terized by intense clinical symptoms, frequent relapse episo-
des and poor quality of life. Aggressive antibacterial therapy is 
warranted to eradicate causative pathogens and to achieve a 
permanent cure. We administered a “switch-therapy” protocol 
to 30 patients showing severe CBP symptoms and two or mo-
re relapse episodes in the previous 12 months. Patients recei-
ved intravenous azithromycin (500 mg/day) and ciprofloxacin 
(800 mg/day) for three days, followed by oral ciprofloxacin (1 
g/day) for 25 days. Twenty-seven (90%) patients showed pat-
hogen eradication at test-of-cure (TOC) visit. Five cases of in-
fection relapse were detected at follow-up. At the TOC visit, 
25 patients (83%) showed mild/absent symptoms, measured 
with the NIH-chronic prostatitis symptom index. These results 
indicate the efficacy of a “switch-therapy” protocol, based on 
combined azithromycin and ciprofloxacin. Comparative stud-
ies on larger CBP patient populations are warranted to confirm 
these encouraging results.
Key words: chronic prostatitis, chronic bacterial prostati-
tis, chronic pelvic pain syndrome, macrolide, fluoroquinolone, 
genitourinary infections, azithromycin, ciprofloxacin, NIH-CPSI
cal systemic hallmarks of acute prostatitis, such as fever, 
chills, malaise and other symptoms.2,3
When severe symptoms are present in CBP patients, ag-
gressive, long-term antibacterial therapy is warranted to 
eradicate causative pathogens, to attenuate the intense 
symptoms, and to achieve a permanent cure.3,4 Fluoroqui-
nolones (FQs) are recommended as first-choice antibacte-
rial agents for treatment of category II CBP. International 
guidelines indicate a 4-12 week course of ciprofloxacin, le-
vofloxacin, norfloxacin or other FQs for treatment of infec-
tion caused by susceptible pathogens.5,3
FQ therapy can achieve pathogen eradication in over 80% 
of cases.6 However, success of antibacterial therapy is of-
ten transient. Relapse occurs frequently, and is caused in 
most cases by incomplete pathogen eradication, probably 
due to insufficient distribution of antibiotics to the pros-
tate, but also possibly due to survival of pathogens in the 
form of bacterial chemoresistant biofilms.7 CBP symptoms 
Introduction
Chronic prostatitis syndromes are serious, invaliding con-
ditions. The quality of life for a man suffering from chronic 
prostatitis is similar to that experienced by patients affect-
ed by myocardial infarction, unstable angina, or Crohn’s 
disease.1 
Symptomatic chronic prostatitis syndromes are general-
ly classified as bacterial or abacterial. Category II chron-
ic bacterial prostatitis (CBP, National Institutes of Health 
[NIH] classification) is diagnosed when uropathogens are 
cultured from a chronically infected prostate in patients 
suffering from repeated symptomatic episodes of bacte-
riuria.2
CBP signs and symptoms may include perineal pain, testic-
ular pain and/or other forms of pelvic pain, irritative and/
or obstructive bladder symptoms, hematuria, pyuria, ejac-
ulatory pain and sexual dysfunction. CBP lacks the typi-
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equal or superior to 17,14 and (ii) two or more relapse epi-
sodes  of CBP occurring in the previous 12 months.
CBP patients were excluded from the study if they present-
ed any of the following conditions: category I acute bac-
terial prostatitis, chronic prostatitis involving Chlamyd-
ia trachomatis, Ureaplasma urealyticum, fungi or proto-
zoa, category III chronic prostatitis/chronic pelvic pain syn-
drome, therapy with antibacterial agents or other medica-
tions effective at the prostatic level within a period of 14 
days prior to prostatitis diagnosis, renal/hepatic/cardiac 
insufficiency (for liver disease: AST/ALT levels twice above 
the upper limit were exclusion criteria), arrhythmia, long 
QT syndrome, indwelling catheters, cystostomy, ureteros-
tomy, previous prostatic surgery or radiotherapy, neopla-
sia, chronic diarrheal disease or any other gastrointestinal 
condition affecting drug absorption. 
Diagnosis
The following data were obtained for each patient: clinical 
history, clinical status (including digitorectal examination) 
and the severity of chronic prostatitis symptoms, scored 
with a Croatian translation of the NIH-CPSI questionnaire, 
rating pain, voiding symptoms and the impact of the dis-
ease on the quality of life of patients. 
Urethral swab specimens and samples of urine and ex-
pressed prostatic secretions (EPS), according to the 
“4-glass” lower urinary tract segmented test15 were collect-
ed in each patient. Quantitative segmented cultures and 
bacterial identification of Gram-negative and Gram-posi-
tive bacteria in first-voided, midstream, and post-massage 
voided urine (VB
3
) specimens and EPS were preformed at 
the Clinical Microbiology Laboratory of the University Hos-
pital for Infectious Diseases “Dr Fran Mihaljević”, Zagreb, 
by standard microbiological techniques.
The number of leukocytes and Gram-positive and Gram-
negative bacteria was determined in 1 ml of urine from the 
segmented test. Expressed prostatic secretions (EPS) and 
urine samples collected immediately after prostatic mas-
sage were also examined for the presence of Chlamydia 
trachomatis, Ureaplasma urealyticum, Mycoplasma hom-
inis and Trichomonas vaginalis. Urethral swab specimens 
were analyzed for Chlamydia trachomatis, Ureaplasma 
urealyticum and Mycoplasma hominis.
Study design and treatment regimen
This prospective, noncomparative open-label pilot study 
was performed on a cohort of 30 CBP patients selected 
on the basis of stringent inclusion/exclusion criteria. All 
patients received a 4-week “switch-therapy” antibacterial 
protocol (post-hoc assessed compliance: 100%), based on 
the administration of intravenous azithromycin (500 mg 
once daily) and intravenous ciprofloxacin (400 mg twice 
daily) for three days, followed by oral ciprofloxacin (500 mg 
twice daily) for 25 days. 
During the course of the study patients received no ad-
ditional medication that would relieve their symptoms, or 
and infection relapses may continue to flare up for months 
or years, with a considerable impact on the quality of life 
of patients. Current research in the field of chronic bac-
terial prostatitis focuses on the optimization of therapeu-
tic protocols aimed at achieving higher eradication rates 
and at minimizing the probability of relapse.8 Over the last 
few years, we have optimized an aggressive antibacteri-
al protocol for CBP, based on the administration of oral 
ciprofloxacin combined with oral azithromycin for 4 to 6 
weeks. This regimen was well tolerated and was charac-
terized by high eradication rates, by rapid and sustained 
symptom relief, and by a low number of recurrences.9-13 
In order to improve the outcome of antibacterial therapy 
in specific cases of CBP characterized by severe clinical 
symptoms concomitant with frequent infection relapses, 
we designed a therapeutic protocol aimed at exploiting (i) 
the effectiveness of the combination of antibacterial fluo-
roquinolones and macrolides, (ii) the important non-anti-
biotic intrinsic properties of macrolides, as well as (iii) the 
complete bioavailability of these antibacterial agents and 
the optimal systemic drug exposure achievable with intra-
venous drug administration. 
Because long-term intravenous treatment is not sustain-
able in CBP patients, a “switch-therapy” protocol was de-
signed to ensure optimal patient compliance.
A pilot study was conducted to investigate the safety and 
the clinical/microbiological efficacy of this therapeutic pro-
tocol.
Patients and methods
This study was conducted at the Outpatient Department 
for Urogenital Infections, University Hospital for Infectious 
Diseases “Dr. Fran Mihaljević’”, Zagreb, Croatia, between 
2008 and 2010. The Ethics Committee of the Hospital ap-
proved the study. An informed consent was signed by all 
patients after counselling.
Inclusion/exclusion criteria
We enrolled patients older than 20 years of age with CBP 
caused by traditional uropathogens and no evidence of an-
atomical abnormality of the genitourinary tract, assessed 
by prostate ultrasound imaging.
Patients were included in this study if they manifested the 
signs and symptoms of category II CBP, according to the 
NIH criteria (National Institute of Diabetes and Digestive 
and Kidney Diseases Chronic Prostatitis Workshop, 1995).
Signs/symptoms included pain or discomfort in the low-
er back and in the perineal, penile, suprapubic, scrotal or 
groin areas, painful ejaculation, dysuria, urinary frequen-
cy, urgency, hesitancy, nycturia, urinary retention or de-
creased urinary stream, prostate asymmetry or tender-
ness. 
Specific inclusion criteria for this study were: (i) severe clin-
ical symptoms, defined as the sum of NIH-Chronic Pros-
tatitis Symptom Index (NIH-CPSI) pain and voiding scores 
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tocol as well as possible adverse events were evaluated 
at the TOC visit, 6 months after completion of therapy and 
whenever adverse effects were spontaneously reported 
by patients.
Sample size and statistical methods
The Wilcoxon signed-rank test (WSRT) was used to analyze 
intragroup differences in NIH-CPSI scores at different time 
points, with an α error of 5% to define significance. One-
tailed analysis was used, as it was only feasible that symp-
toms of untreated bacterial prostatitis patients would at-
tenuate upon aggressive antibacterial therapy.
A priori sample size computation was performed, based 
on a minimally acceptable estimated effect size of -0.91, 
corresponding to a “slight symptom improvement” scored 
with the NIH-CPSI test, according to Propert et al.16 A sam-
ple size of 10 was adequate for a one-tailed analysis, with 
a 5% α error probability and 80% 1-β error probability.
The XLStatistics 5.71 program (http://www.deakin.edu.
au/~rodneyc/XLStatistics/) was used for statistical infer-
ence; the G*Power 3.1 software17 was used for a priori and 
post-hoc statistical power analysis.
Results
The median age of enrolled patients was 51 (range: 27-
65). At the baseline visit, 27 and 3 patients manifested 
single-pathogen and double-pathogen infections, respec-
tively. The baseline median NIH-CPSI total score of the pa-
tient population was 32 (range: 25-38).
Table 1 shows the microbiological presentation of patients 
at the end of treatment (test-of-cure visit) and at follow-up. 
Twenty-seven patients (90%) showed eradication of caus-
would act as a confounder during evaluation of the clinical 
endpoints of the study. Clinical and microbiological work-
up was performed 4-6 weeks (test-of-cure [TOC] visit) and 
6 months (Follow-up [FU] visit) after the last ciprofloxacin 
dose. 
Clinical efficacy endpoints and 
microbiological response definitions
Microbiological efficacy was the primary outcome of this 
study. The pathogen loads in expressed prostatic secre-
tions (EPS) or in bladder urine specimens collected imme-
diately after prostatic massage (VB
3
) were microbiologi-
cal outcome measures. A bacterial count inferior to 103 
CFU/ml in EPS or VB
3
 defined microbiological eradication. 
If only Gram-positive cocci were found (with the excep-
tion of Enterococci and Staphylococcus aureus), a bacte-
rial count inferior to 104 CFU/ml was the eradication cri-
terion. Microbiological persistence was defined as bac-
terial counts of causative pathogen equal or superior to 
eradication thresholds. Eradication with superinfection 
was defined as baseline pathogen eradicated (<103 CFU/
ml or <104 CFU/ml if Gram-positive cocci, with the excep-
tion of Enterococci and S. aureus) with appearance of a 
new pathogen (≥103 CFU/ml or ≥104 CFU/ml if Gram-pos-
itive cocci).
Clinical efficacy, the secondary outcome of the study, was 
measured using the NIH-CPSI. The clinical efficacy end-
point was the sum of NIH-CPSI pain and voiding symp-
tom scores, categorized into mild (0 to 9 points), moderate 
(10 to 16 points) and severe (17 to 31 points) according to 
McNaughton Collins et al.14 Statistical significance of de-
creases in NIH-CPSI total scores, pain + voiding scores or 
quality of life impact scores was also calculated by non-
parametric analysis. Tolerability of the experimental pro-
Table 1. Microorganisms isolated from prostate-specific specimens and per-pathogen eradication data in 30 CBP patients subjected to the switch the-
rapy experimental protocol at test-of-cure visit (4-6 weeks after the last dose of ciprofloxacin) and at follow-up visit (six months after the 
end of therapy)
Microorganism Number of patients
Test-of-cure visit Follow-up visit
E P ES/P E P ES/P
Enterococcus faecalis 8 1 0 8 0 1
Escherichia coli 7 1 0 6 1 1
Proteus mirabilis 3 0 0 3 0 0
Klebsiella pneumoniae 2 1 0 3 0 0
Citrobacter spp. 2 0 0 2 0 0
Enterobacter spp. 2 0 0 2 0 0
Pseudomonas aeruginosa 1 0 0 0 0 1
E. coli + E. faecalis 1 0 0 0 0 1
P. aeruginosa + E. faecalis 1 0 0 0 0 1
Total 27 (90%) 3 (10%) - 24 (80%) 1 (3,3%) 5 (16,7%)
E - eradication; P - persistence; ES/P - eradication with superinfection, (or persistence following apparent eradication)
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We performed post-hoc “compromise” power analysis18 
to assess whether statistical inference about clinical im-
provement scores was characterized by adequate power. 
We computed the achieved power given α=0.05, a sample 
size of 30 subjects, q=β/α=4, and effect sizes of (i) 2.57 
and 2.22 calculated for the comparison of baseline NIH-
CPSI total scores with TOC and follow-up data, respective-
ly, (ii) 2.35 and 2.17, for the comparison of baseline NIH-
CPSI clinical symptoms (pain + voiding) scores with TOC 
and follow-up data, respectively, and (iii) 1.81 and 1.68, 
for the comparison of baseline NIH-CPSI quality of life im-
pact scores with TOC and follow-up data, respectively. 
Comparisons were shown to be adequately powered (1-
β>0,99 in all cases).
Discussion
Intravenous administration of antibacterial agents is cur-
rently reserved for cases of acute bacterial prostatitis. In-
ternational guidelines recommend parenteral adminis-
tration of high doses of bactericidal antibiotics, such as 
broad-spectrum penicillins, third-generation cephalospo-
rins or fluoroquinolones, combined or not  with an amino-
glycoside.3,4,5 After defervescence and normalization of in-
fection parameters, treatment can be switched to oral an-
tibiotics, and continued for about 2-4 weeks.3,4,5
The present pilot study was aimed at assessing whether 
a switch-therapy regime could also be suitable for severe 
cases of chronic bacterial prostatitis. The results present-
ed in this paper demonstrated the efficacy and safety of a 
4-week therapy protocol based on the intravenous admin-
istration of ciprofloxacin and azithromycin, followed by oral 
ciprofloxacin. Microbiological eradication was achieved 
in 90% of patients (27 out of total 30 enrolled subjects). 
This effect was associated with prompt resolution of se-
vere CBP symptoms, assessed with the NIH-CPSI test. In 
three cases of multiple infection, apparent microbiologi-
cal eradication at test-of-cure visit was followed by reap-
pearance of the same pathogens assessed at baseline. 
Interestingly, in all other cases, no infection relapse has 
been reported to this day (about 12 months off-therapy). 
The most likely reasons for relapse of infection in CBP are 
the relatively low prostatic concentrations of antibiotics 
achievable with currently available oral agents and dos-
ages, or the persistence of pathogens within the prostate 
gland in the form of quorum-sensing regulated biofilms.19 
Compared to planctonic pathogens, sessile bacterial bio-
films are characterized by different metabolic patterns 
and by reduced susceptibility to antibacterial agents. The 
administration of agents able to dissolve or inhibit bio-
films, or the achievement of increased serum and, in turn, 
tissue concentrations of antibiotics are two conceivable 
therapeutic approaches to relapsing CBP. Both approach-
es were attempted by administering fluoroquinolones and 
macrolides intravenously.
Macrolide antibiotics do not only provide clinical benefit in 
chronic bacterial infections as a result of direct antibacte-
rial effects. They exhibit biofilm inhibiting effects, as well 
ative pathogens at the TOC visit, and 3 showed microbi-
ological persistence. Six months after the end of thera-
py bacterial infection was detected in 6 patients. In one 
case the same baseline pathogen type (E. coli) persisted 
throughout the whole study. In two cases eradication of 
the baseline pathogen with superinfection by a different 
organism was observed, whereas in three cases baseline 
pathogens, apparently eradicated at the TOC visit, were 
detected during the follow-up visit.
All enrolled patients had severe symptoms at baseline 
as inclusion criterion. NIH-CPSI pain + voiding scores 
ranged between 19 and 29, and total scores ranged be-
tween 25 and 38. The antibacterial switch-therapy pro-
tocol caused a marked attenuation of CBP clinical symp-
toms, measured with the NIH-chronic prostatitis symptom 
index. At the TOC visit, 25 patients (83%) showed mild or 
absent symptoms, whereas 5 patients (17%) showed per-
sistence of severe symptoms (Fig. 1). No patient had mod-
erate symptoms. At the 6-month follow-up visit, two more 
patients showed severe symptoms (23%), whereas the re-
maining 23 persisted in a condition of symptom remission 
(Fig. 1). The decrease of pain + voiding scores, of quality of 
life impact scores and of NIH-CPSI total scores in the en-
tire patient cohort was statistically significant in all cases 
(p<0.01, baseline vs. TOC scores; p<0.01, baseline vs. fol-
low-up scores, Wilcoxon signed rank test).
Figure 1. Clinical efficacy of a 4-week switch-therapy protocol ba-
sed on administration of intravenous azithromycin (500 
mg once-daily) and ciprofloxacin (400 mg twice-daily) for 
three days, followed by oral ciprofloxacin (500 mg twice-
daily) for 25 days. The NIH-CPSI questionnaire was ad-
ministered to 30 patients at enrolment, at the test-of-cu-
re visit (4-6 weeks after the last ciprofloxacin dose), and at 
the follow-up visit, 6 months after the end of therapy. Cli-
nical symptoms are presented as the sum of pain and voi-
ding symptom scores. According to McNaughton Collins et 
al.,14 symptoms were classified as mild (0-9 points), mo-
derate (10-16 points) and severe (17-31 points). Patients of 
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It is important to emphasize that azithromycin shows 
unique pharmacokinetic/pharmacodynamic (PK/PD) prop-
erties, compared to other macrolide antibiotics. Whereas 
erythromycin shows a time-dependent antibacterial activ-
ity, the AUC24/MIC is the primary factor influencing the 
clinical efficacy of azithromycin.30,31 Therefore, azithromy-
cin behaves like ciprofloxacin, which shows a concentra-
tion-dependent killing activity, and was co-administered 
with the macrolide. 
In conclusion, elevated peak plasma concentrations 
achieved with intravenous administration may possibly 
lead to increased prostatic concentrations of both azithro-
mycin and ciprofloxacin, and ultimately to enhanced anti-
bacterial, antibiofilm and anti-inflammatory activity of the 
tested drug combination. As no adverse effects were re-
corded or spontaneously reported by patients, increased 
drug concentrations apparently did not cause the emer-
gence of signs of toxicity. Due to the noncomparative de-
sign of our study, these results should be evaluated con-
servatively and confirmed in a randomized controlled set-
ting.
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as a variety of immunomodulatory actions which promote 
host defense.20-24 These effects of macrolides are well 
known and extensively exploited in the treatment of pul-
monary conditions. In cystic fibrosis and bronchiolitis ob-
literans, combined actions of macrolides probably result 
in increased clinical efficacy than their direct antibacteri-
al actions alone.25 
Azithromycin is an inhibitor of the generation of auto-in-
ducing, quorum-sensing homoserine lactone molecules 
that regulate bacterial growth and biofilm production,22,23 
and can also prevent the production of alginate, the most 
prominent component of biofilm, via inhibition of GDP-
mannose dehydrogenase. In addition, azithromycin can 
stimulate neutrophils, thereby promoting acute antibacte-
rial defense, but subsequently inhibits several neutrophil-
synthesized inflammatory chemokines and cytokines20,22 
and promotes neutrophil apoptosis, which helps to resolve 
inflammation.26,27 In summary, these pleiotrophic effects 
of azithromycin, combined with their intrinsic antibacteri-
al properties and with the bactericidal activity of ciproflox-
acin may have concurred to the high eradication rates ob-
served in our patient cohort. 
When administered orally, azithromycin shows ~ 40% bio-
availability, due to incomplete drug absorption.28 Follow-
ing single oral doses of 500 mg azithromycin, Cmax and 
AUC24 were reported to be 0.41 μg/ml and 2.6 μg ·h/ml, 
respectively.  These values are approximately 38% and 
52% of the values observed following a single 500 mg 
3-hour intravenous infusion (Cmax: 1.08 μg/ml, AUC24: 
5.0 μg ·h/ml).29 
Increased bioavailability and higher peak plasma con-
centrations achieved upon intravenous administration of 
azithromycin may also have concurred to the favorable mi-
crobiological and clinical results of treatment.
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